布列维肽治疗慢性HDV感染1例

N. A. Illarionova, S. S. Sleptsova
{"title":"布列维肽治疗慢性HDV感染1例","authors":"N. A. Illarionova, S. S. Sleptsova","doi":"10.25298/2616-5546-2023-7-1-89-92","DOIUrl":null,"url":null,"abstract":"Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate of antibodies to the delta virus is 35% [3]. The urgency of the problem of HDV infection is also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug for the treatment of chronic delta hepatitis, was registered in Russia. Three randomized trials showed a high rate of virological, biochemical response, as well as good tolerability and safety. Objective – to evaluate the efficacy and safety of Bulevirtide in the treatment of chronic HDV infection. Material and methods. A clinical case of a patient L. suffering from a chronic form of HDV infection receiving antiviral therapy is presented. Results. Bulevirtide demonstrated high efficacy, as evidenced by the development of a virological response during the first 14 weeks of therapy and a decrease in HDV RNA to an undetectable level within 29. Conclusions. It is necessary to widely introduce Bulevirtide for the treatment of patients with chronic delta hepatitis due to its high efficacy and safety.","PeriodicalId":34878,"journal":{"name":"Gepatologiia i gastroenterologiia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A CLINICAL CASE OF BULEVIRTIDE THERAPY FOR CHRONIC HDV-INFECTION\",\"authors\":\"N. A. Illarionova, S. S. Sleptsova\",\"doi\":\"10.25298/2616-5546-2023-7-1-89-92\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate of antibodies to the delta virus is 35% [3]. The urgency of the problem of HDV infection is also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug for the treatment of chronic delta hepatitis, was registered in Russia. Three randomized trials showed a high rate of virological, biochemical response, as well as good tolerability and safety. Objective – to evaluate the efficacy and safety of Bulevirtide in the treatment of chronic HDV infection. Material and methods. A clinical case of a patient L. suffering from a chronic form of HDV infection receiving antiviral therapy is presented. Results. Bulevirtide demonstrated high efficacy, as evidenced by the development of a virological response during the first 14 weeks of therapy and a decrease in HDV RNA to an undetectable level within 29. Conclusions. It is necessary to widely introduce Bulevirtide for the treatment of patients with chronic delta hepatitis due to its high efficacy and safety.\",\"PeriodicalId\":34878,\"journal\":{\"name\":\"Gepatologiia i gastroenterologiia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gepatologiia i gastroenterologiia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25298/2616-5546-2023-7-1-89-92\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gepatologiia i gastroenterologiia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25298/2616-5546-2023-7-1-89-92","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景萨哈共和国(雅库特)是慢性丙型肝炎的流行地区,德尔塔病毒抗体的检测率为35%[3]。HDV感染问题的紧迫性也由其侵袭性和快速进展的过程决定。2019年,治疗慢性德尔塔型肝炎的药物Bulevitide在俄罗斯注册。三项随机试验显示了高的病毒学和生化反应率,以及良好的耐受性和安全性。目的:评价博韦肽治疗慢性HDV感染的疗效和安全性。材料和方法。介绍了一例患有慢性HDV感染的患者L.接受抗病毒治疗的临床病例。后果在治疗的前14周出现病毒学反应,HDV RNA在29周内降至检测不到的水平,证明了布韦肽具有很高的疗效。结论。布列韦肽治疗慢性德尔塔型肝炎疗效高、安全性好,有必要广泛应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A CLINICAL CASE OF BULEVIRTIDE THERAPY FOR CHRONIC HDV-INFECTION
Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate of antibodies to the delta virus is 35% [3]. The urgency of the problem of HDV infection is also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug for the treatment of chronic delta hepatitis, was registered in Russia. Three randomized trials showed a high rate of virological, biochemical response, as well as good tolerability and safety. Objective – to evaluate the efficacy and safety of Bulevirtide in the treatment of chronic HDV infection. Material and methods. A clinical case of a patient L. suffering from a chronic form of HDV infection receiving antiviral therapy is presented. Results. Bulevirtide demonstrated high efficacy, as evidenced by the development of a virological response during the first 14 weeks of therapy and a decrease in HDV RNA to an undetectable level within 29. Conclusions. It is necessary to widely introduce Bulevirtide for the treatment of patients with chronic delta hepatitis due to its high efficacy and safety.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
15
审稿时长
2 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信